6 days Ago By ABMN Staff
Wellington Management Group LLP reduced its stake in Ardelyx, Inc. ( NASDAQ:ARDX – Free Report ) by 9.2% in the fourth quarter, Holdings Channel.
com reports. The fund owned 107,345 shares of the biopharmaceutical company’s stock after selling 10,925 shares during the period. Wellington Management Group LLP’s holdings in Ardelyx were worth $544,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also added to or reduced their stakes in ARDX. Orion Portfolio Solutions LLC grew its position in shares of Ardelyx by 42.7% during the 4th quarter.
Orion Portfolio Solutions LLC now owns 16,486 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 4,933 shares in the last quarter. EntryPoint Capital LLC boosted its position in Ardelyx by 103.2% during the fourth quarter.
EntryPoint Capital LLC now owns 33,323 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 16,924 shares during the period. Sheets Smith Investment Management bought a new position in Ardelyx during the 4th quarter worth approximately $58,000. Vanguard Group Inc.
grew its holdings in Ardelyx by 5.6% in the 4th quarter. Vanguard Group Inc.
now owns 14,362,659 shares of the biopharmaceutical company’s stock worth $72,819,000 after acquiring an additional 767,111 shares during the last quarter. Finally, Fox Run Management L.L.
C. grew its position in shares of Ardelyx by 214.5% in the 4th quarter.
Fox Run Management L.L.C.
now owns 41,531 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 28,324 shares during the last quarter. Institutional investors own 58.92% of the company’s stock.
Wall Street Analyst Weigh In Several equities research analysts recently weighed in on the company. LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $11.00 price target on shares of Ardelyx in a research note on Friday, March 7th.
BTIG Research initiated coverage on shares of Ardelyx in a report on Tuesday, March 4th. They set a “buy” rating and a $14.00 price target on the stock.
Jefferies Financial Group cut their price target on Ardelyx from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, January 2nd.
Raymond James reissued a “strong-buy” rating and issued a $13.00 target price (down from $15.00) on shares of Ardelyx in a report on Friday, February 21st.
Finally, HC Wainwright reiterated a “neutral” rating and set a $5.50 price objective on shares of Ardelyx in a research report on Friday, February 21st. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock.
According to data from MarketBeat, Ardelyx has an average rating of “Moderate Buy” and an average price target of $10.61. Ardelyx Trading Up 2.
5 % Shares of ARDX opened at $4.57 on Tuesday. The company has a 50-day moving average of $5.
20 and a 200 day moving average of $5.37. The company has a debt-to-equity ratio of 0.
87, a current ratio of 4.58 and a quick ratio of 4.31.
Ardelyx, Inc. has a 1-year low of $4.02 and a 1-year high of $9.
33. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -28.
56 and a beta of 0.81. Ardelyx ( NASDAQ:ARDX – Get Free Report ) last released its quarterly earnings data on Thursday, February 20th.
The biopharmaceutical company reported $0.02 earnings per share for the quarter, meeting the consensus estimate of $0.02.
Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%.
The firm had revenue of $116.13 million during the quarter, compared to the consensus estimate of $111.16 million.
On average, research analysts expect that Ardelyx, Inc. will post -0.18 EPS for the current year.
Insider Activity In other news, CEO Michael Raab sold 41,666 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.36, for a total transaction of $223,329.
76. Following the sale, the chief executive officer now owns 1,108,719 shares in the company, valued at approximately $5,942,733.84.
The trade was a 3.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink .
Also, Director David M. Mott bought 199,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were bought at an average cost of $4.
99 per share, for a total transaction of $993,010.00. Following the transaction, the director now owns 1,937,765 shares in the company, valued at $9,669,447.
35. The trade was a 11.44 % increase in their position.
The disclosure for this purchase can be found here . In the last three months, insiders have sold 158,076 shares of company stock worth $823,804. 5.
90% of the stock is currently owned by company insiders. Ardelyx Profile ( Free Report ) Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
Read More Want to see what other hedge funds are holding ARDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ardelyx, Inc. ( NASDAQ:ARDX – Free Report ).
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter ..
